Prime Capital Investment Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Prime Capital Investment Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.65M	Sell	42,490 -50,427	-54%	-$5.22M	0.05%	245
2026 Q1	$9.65M	Sell	92,917 -1,206	-1%	-$128K	0.11%	154
2025 Q4	$9.71M	Sell	94,123 -2,742	-3%	-$267K	0.12%	137
2025 Q3	$8.75M	Sell	96,865 -5	-0%	-$438	0.11%	140
2025 Q2	$8.52M	Sell	96,870 -34,805	-26%	-$3.02M	0.11%	142
2025 Q1	$12M	Buy	131,675 +4,877	+4%	+$439K	0.14%	129
2024 Q4	$10.9M	Sell	126,798 -2,646	-2%	-$239K	0.16%	105
2024 Q3	$12.3M	Sell	129,444 -4,846	-4%	-$460K	0.18%	100
2024 Q2	$12.3M	Sell	134,290 -5,976	-4%	-$534K	0.18%	97
2024 Q1	$12.7M	Sell	140,266 -1,828	-1%	-$160K	0.18%	105
2023 Q4	$11.6M	Sell	142,094 -6,056	-4%	-$475K	0.17%	112
2023 Q3	$11.8M	Buy	148,150 +1,800	+1%	+$145K	0.24%	86
2023 Q2	$11.5M	Buy	+146,350	New	+$11.5M	0.23%	92
2023 Q1	–	Sell	-151,536	Closed	-$11.8M	–	632
2022 Q4	$11.8M	Buy	+151,536	New	+$11.2M	0.45%	56

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Prime Capital Investment Advisors's PPH Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its VanEck Pharmaceutical ETF (PPH) stake by 54% in Q2 2026, selling an estimated $5.22M and leaving 42,490 shares worth $4.65M. The position accounts for 0.05% of the portfolio, ranked #245.

Prime Capital Investment Advisors first reported a position in PPH in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.7M in Q1 2024. 147 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Prime Capital Investment Advisors held 42,490 shares of VanEck Pharmaceutical ETF worth $4.65M as of Q2 2026.
Prime Capital Investment Advisors sold 50,427 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $5.22M.
VanEck Pharmaceutical ETF made up 0.05% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #245 holding.
Prime Capital Investment Advisors first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and has held it in 14 quarters since.
Prime Capital Investment Advisors's VanEck Pharmaceutical ETF position peaked at $12.7M in Q1 2024.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.